Open AccessThe effectiveness of targeted therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer
Author(s) -
Anna V. Ovodova,
Ю. Ю. Петухова,
Е. В. Елисеева,
О. В. Переломова
Publication year - 2020
Publication title -
tihookeanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
ISSN - 1609-1175
DOI - 10.34215/1609-1175-2020-4-55-58
Subject(s) - bevacizumab , folfox , medicine , colorectal cancer , oncology , chemotherapy , life expectancy , stage (stratigraphy) , cancer , oxaliplatin , population , paleontology , environmental health , biology
Objective: To estimate the effectiveness of the target therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer. Methods : Life expectancy of 208 patients having 3rd and 4th stages was retrospectively analyzed. They received different kinds of treatment: FOLFOX, canecitabin with FOLFOX combined with bevacizumab. Results : Average life expectancy of the patients having 3rd stage of colorectal cancer is 11.4 months of those who applied FOLFOX scheme, and 14.4 months taking “FOLFOX+bevacizumab” scheme. Of those patients having the 4th stage of cancer this combination of chemotherapy and target medicine resulted in an increase in life expectancy for 3.7 months. Conclusions : Inclusion of bevacizumab in treatment plan of the patients having 3rd and 4th stages of colorectal cancer improves life expectancy indexes of the patients.